The one substantive regulatory item for the desk today is a new practice guideline. The American Academy of Neurology Guidelines Subcommittee and the American Headache Society have published updated recommendations on pharmacological migraine prevention in adults, developed by a multidisciplinary panel through the AAN's formal process, with the underlying systematic review published alongside it and covering studies to June 2024.
The scope is broader than a drug ranking, which is what makes it useful. It addresses when it is appropriate to start a preventive medication at all, and how to choose between them. It then works through the situations where the choice is actually difficult: patients with fibromyalgia, obesity or hypertension, where a preventive can treat two problems or worsen one; older adults; pregnancy and lactation; sex-related factors in drug selection; and patients with medication overuse, where prevention interacts with withdrawal. It closes with recommendations on assessing efficacy and adverse effects, and on when and how to stop.
That last part deserves attention, because stopping is the step most often neglected. Preventives are frequently continued indefinitely by default, long after the episode that justified them, accumulating side effects and cost. A guideline that treats discontinuation as a decision requiring evidence rather than a lapse in follow-up is doing something genuinely useful.
Read alongside the head-to-head trial above, the practical picture is coherent: start prevention when frequency and disability justify it, choose the agent by comorbidity and tolerability rather than habit, assess honestly at a defined point, and stop when it is no longer earning its place.
- Decide whether prevention is indicated at all before deciding which drug — frequency and disability, not patient request.
- Let comorbidity drive the choice: obesity, hypertension, fibromyalgia and pregnancy each change the right answer.
- Address medication overuse alongside starting prevention, not after it.
- Set a defined point at which you will assess efficacy, and hold yourself to it.
- Plan discontinuation explicitly; preventives should not be continued indefinitely by default.
The statistics, in plain English
This is a formally developed practice guideline, which sits above a consensus statement and below a trial in what it can tell you. Its recommendations rest on a systematic review with a literature cut-off of June 2024, so evidence published since — including the head-to-head comparison of atogepant and topiramate above — is not incorporated. That is a normal limitation of guideline development rather than a flaw, but it means a recommendation and a newer trial can legitimately point in slightly different directions.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free